The impact of COVID-19 treatment scarcity on the willingness to be take a treatment

How to cite

Thunstrom, Linda; Ashworth, Madison; Newbold, Stephen; Shogren, Jason; Cherry, Todd; Finnoff, David. 2022. "The impact of COVID-19 treatment scarcity on the willingness to be take a treatment." AEA RCT Registry. AEARCTR-0009164. https://doi.org/10.1257/rct.9164-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Linda Thunstrom* , Madison Ashworth , Stephen Newbold , Jason Shogren , Todd Cherry , David Finnoff

* Primary investigator

Registry ID
AEARCTR-0009164
DOI
https://doi.org/10.1257/rct.9164-1.0
First registered
Last updated
Status
In development
Trial dates
2022-03-25 – 2022-04-07
Countries
Private
JEL codes
D12, I12
Registry record
http://www.socialscienceregistry.org/trials/9164

Abstract

This study examines the willingness to take COVID-19 treatments, in a context where treatments are new and in short supply. When treatments are in short supply, people will often have difficulties accessing treatments, and even more difficulties accessing their preferred treatment. We examine how people's willingness to take a COVID-19 treatment is affected by there being multiple treatments on the market, but only one of the treatments (which may or may not be the most effective treatment) is available for a person to take. Further, COVID-19 treatments (as opposed to the vaccines) need to be prescribed by providers. Providers will, however, often lack experience with the treatments, due to their novelty, and therefore may be more reluctant to prescribe them. Given family physicians are generally a highly trusted source of health information, we are particularly interested in knowing the impact on people's willingness to take a COVID-19 treatment from the treatment being prescribed by their family physician, versus another physician.

Intervention

We will describe two treatments (A and B) that are available to treat COVID-19. Participants may then learn either (1) that treatment A is available to them, (2) treatment B is available to them, or (3) both treatment A and B are available to them. Further, participants will be informed that the treatments are prescribed either by their family physician, or that their family physician was unwilling to prescribe the treatment but that it has been subscribed by another physician.

Experimental design

We will vary the treatment that is available to participants (Treatment A, B or both) and whether the treatment is prescribed by their family physician or another physician. Hence, we have a 3x2 experimental design, and participants will be randomized into one of six treatment arms:

-- treatment A is available and is prescribed by family physician
-- treatment B is available and is prescribed by family physician
-- treatment A and B is available and either is prescribed by family physician
-- treatment A is available but is not prescribed by family physician
-- treatment B is available but is not prescribed by family physician
-- treatment A and B is available but neither is prescribed by family physician

Design details

Randomization method
Computer.
Randomization unit
Individual.
Clusters
None.
Observations
1500 individuals.
Arms
250 individuals by treatment arm.
Primary outcomes
Stated willingness to take a COVID-19 treatment across severity of COVID-19 symptoms.

Cited by

No citation data available for this registration yet.

Keywords